Sebastian Amigorena

Scientific Co-Founder at Mnemo Therapeutics

Sebastian Amigorena, PhD is Scientific Co-Founder of Mnemo. Sebastian has over 25 years of expertise in immunology and cell biology research. In his graduate and post-doctoral studies, he analyzed the functions of IgG receptors and described the molecular basis of their inhibitory properties. He analyzed dendritic cells’ endocytic and phagocytic pathways and described several unique specializations of both pathways, making significant contributions to our understanding of antigen presentation. Sebastian and his team also contributed to the analysis of cytotoxic T cell dynamic migration in vivo, during the initiation of immune responses in lymph nodes and during the invasion and rejection of solid tumors. More recently, he contributed to understanding the biological role of regulatory T cells, and the epigenetic programming of T cell functions, including memory. After completing a 3-year postdoctoral position at Yale University, Sebastian worked at Inserm AVENIR and became head of the Immunology department (INSERM U932, “Cancer Immunity”) at Institut Curie in 2003, and of the Center for Cancer Immunotherapy in 2017. Sebastian obtained his PhD in Biochemistry at Paris Diderot University in 1990.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Mnemo Therapeutics

1 followers

Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.


Industries

Headquarters

Paris, France

Employees

51-200

Links